Redhill Biopharma
RDHL
51 hedge funds and large institutions have $12.5M invested in Redhill Biopharma in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 16 closing their positions.
44% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $757K
0% less ownership
Funds ownership: 0% → 0% (-0%)
4% less funds holding
Funds holding: 53 → 51 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
49% less capital invested
Capital invested by funds: $24.5M → $12.5M (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$700K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$560K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$452K |
| 4 |
Barclays
London,
United Kingdom
|
+$308K |
| 5 |
AGM
Alpine Global Management
New York
|
+$260K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$1.81M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.12M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$354K |
| 4 |
HJIM
Henry James International Management
New York
|
-$344K |
| 5 |
GS
Gagnon Securities
New York
|
-$296K |
RDHL Hedge Fund Activity: Q4 2021 in Review
51 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2021, worth a combined $12.5M — down 49% from $24.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RDHL and 14 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $700K. The largest seller was Ibex Investors, cutting an estimated $1.81M.
- 51 institutional investors held Redhill Biopharma (RDHL) as of Q4 2021, down from 53 in Q3 2021.
- Funds reported $12.5M of Redhill Biopharma stock for Q4 2021, down 49% quarter-over-quarter.
- 14 funds opened new Redhill Biopharma positions in Q4 2021 and 16 closed out, a net change of -2 holders.
- The largest Redhill Biopharma buyer in Q4 2021 was Millennium Management, an estimated $700K added.
- The largest Redhill Biopharma seller in Q4 2021 was Ibex Investors, an estimated $1.81M sold.
Based on aggregated 13F filings for Q4 2021.